See You in Chicago 2019`
The 2019 National Patient Education Conference will be July 19-21 in Chicago! Will you join us?

Click here to learn more >>

Stepping Out to Cure Scleroderma
Take a Step for Scleroderma

Find a "Stepping Out to Cure Scleroderma" walk/run near you today!

Click here to get started >>

Who We Are

The Scleroderma Foundation is a federally qualified 501(c)(3) nonprofit dedicated to serving the needs of the scleroderma community.  Our primary goal is to raise funds and awareness for our three-fold mission of support, education and research.  All donations are qualified charitable donations to the fullest extent of the law.  Our federal tax identification number is 52-1375827.  All donations are gratefully accepted. 

What is Scleroderma?

Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. The word “scleroderma” comes from two Greek words: “sclero” meaning hard, and “derma” meaning skin. Hardening of the skin is one of the most visible manifestations of the disease.

Read more >>

Download Our Free Scleroderma Information Packet

Can’t download It? Have us mail you a copy!


 

News

Visit the eLetter Archive to read the stories behind these headlines.  Submit your email address to receive the eLetter every week.

eLetter #779; September 14, 2018
  • Conference Videos:  "Esclerodermia: Conceptos fundamentales para entender la enfermedad"
  • Outstanding National Advocates:  Dee Burlile and Shelley Van Pelt
  • Emergency Preparedness & Water Damage Recovery Issues
  • Research & Treatment Centers: Mayo Clinic Rheumatology
  • Submit a Video Sharing Your Perspectives on Rare Disease Advocacy (NORD)
  • Kids Get Scleroderma Too: October 26 & 27, Aurora, Colorado
  • WEBINAR:  "What in the World is New with Scleroderma?" October 18, 2018; 7 - 9 p.m. ET
  • "Newly Diagnosed, Need Support" Inspire.com
  • Stepping Out Walks in September
  • Scleroderma Research Grant Deadline is September 17
  • CLINICAL TRIAL PARTICIPATION
    • Scleroderma Lung Study III
  • PHARMACEUTICAL INDUSTRY NEWS
    • F.D.A. Grants Fast Track Designation to FCX-013

 

E-Newsletter Signup

Get the latest news.

Please leave this field empty

Our Sponsors